Research programme: nitric oxide scavengers - Curacyte
Latest Information Update: 01 May 2007
At a glance
- Originator Curacyte AG
- Developer Curacyte AG; Curacyte Inc
- Class
- Mechanism of Action Nitric oxide inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Uveitis
Most Recent Events
- 01 May 2007 Discontinued - Preclinical for Uveitis in USA (unspecified route)
- 10 Jun 2002 VitaResc Biotech has been acquired by, and merged into, Curacyte AG
- 31 Oct 2001 Preclinical development for Uveitis in USA (unspecified route)